Mercer Global Advisors Inc. ADV Acquires Shares of 15,000 SI-BONE, Inc. (NASDAQ:SIBN)

Mercer Global Advisors Inc. ADV bought a new stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,000 shares of the company's stock, valued at approximately $210,000.

Other hedge funds have also added to or reduced their stakes in the company. Mainstream Capital Management LLC bought a new stake in shares of SI-BONE during the 4th quarter valued at about $53,000. R Squared Ltd bought a new stake in shares of SI-BONE during the 4th quarter valued at about $73,000. KLP Kapitalforvaltning AS bought a new stake in shares of SI-BONE during the 4th quarter valued at about $97,000. Proficio Capital Partners LLC bought a new stake in shares of SI-BONE during the 4th quarter valued at about $155,000. Finally, AlphaQuest LLC boosted its position in shares of SI-BONE by 13,950.6% during the 4th quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock valued at $164,000 after acquiring an additional 11,579 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company's stock.

SI-BONE Price Performance

NASDAQ:SIBN traded down $0.70 during mid-day trading on Thursday, reaching $18.42. The stock had a trading volume of 288,709 shares, compared to its average volume of 375,002. The firm has a 50 day moving average price of $15.17 and a two-hundred day moving average price of $15.17. The stock has a market capitalization of $784.97 million, a P/E ratio of -20.02 and a beta of 0.82. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $20.05. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. As a group, analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Insider Buying and Selling

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,459 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $19.66, for a total value of $68,003.94. Following the completion of the sale, the senior vice president now owns 264,636 shares in the company, valued at approximately $5,202,743.76. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Anthony J. Recupero sold 3,311 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares of the company's stock, valued at $4,026,453.25. The trade was a 1.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 92,565 shares of company stock worth $1,669,871 in the last quarter. 4.00% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th. Truist Financial lifted their price target on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.